Publications
Partners
India approved a locally developed, needle-free and nasally administered Covid-19 vaccine for emergency use on Tuesday, in a boost to the country's homegrown pharmaceutical industry.
The new inoculation was developed by Bharat Biotech, the makers of another intravenous vaccine that was greenlit by the World Health Organisation last November.
India's drug regulator gave the new product emergency authorisation on Tuesday, which will allow it to be used as a primary dose by any unvaccinated or partially vaccinated adult, but not as a booster.
Bharat Biotech conducted third-phase trials in 14 sites around India and found that its safety was "highly comparable" to other vaccines, the company said in a statement.
READ | Covid-19: So, what do we do with all of our masks now that they are no longer required?
Development data would be submitted to peer-reviewed journals and released publicly, the statement added.
It remains unclear when the product will be available for public use, with the company saying it would be rolled out in "due course".
The announcement comes two days after China launched the world's first inhalable Covid vaccine, Convidecia Air, which is administered through a nebuliser.
More than 200 000 people in India died within a few weeks, according to official figures, though experts believe the real toll is several times higher.
India has since administered more than two billion vaccine doses, fully inoculating more than two-thirds of its 1.4 billion population.
